Bone destruction induced by the metastasis of breast cancer cells is a frequent complication that is caused by the interaction between cancer cells and bone cells. Receptor activator of nuclear factor kappa-B ligand (RANKL) and the endogenous soluble RANKL inhibitor, osteoprotegerin (OPG), directly play critical roles in the differentiation, activity, and survival of osteoclasts. In patients with bone metastases, osteoclastic bone resorption promotes the majority of skeletal-related events and propagates bone metastases. Therefore, blocking osteoclast activity and differentiation via RANKL inhibition can be a promising therapeutic approach for cancer-associated bone diseases. We investigated the potential of isoliquiritigenin (ISL), which has anti-proliferative, anti-angiogenic, and anti-invasive effects, as a preventive and therapeutic agent for breast cancer cell-induced bone destruction. ISL at non-toxicity concentrations significantly inhibited the RANKL/OPG ratio by reducing the production of RANKL and restoring OPG production to control levels in hFOB1. 
INTRODUCTION
Bone metastasis from breast cancer leads to severe bone destruction through the interaction between cancer cells and bone cells. 1 Osteolytic bone destruction significantly decreases the survival rate of patients with metastatic breast cancer. 2 Receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) are key molecules in bone-resorbing osteoclast differentiation and activation. RANKL from osteoblasts binds to receptor activator of nuclear factor kappa-B (RANK) on the surface of preosteoclasts and promotes the maturation of osteoclasts. OPG secreted by osteoblasts obstructs the binding of RANKL and RANK. Whereas a balance between RANKL and OPG is maintained in normal physiology, various cytokines or chemokines secreted by breast cancer cells disrupt the balance between RANKL and OPG. 3 Consequently, the number of bone-resorbing osteoclasts and bone destruction are abnormally increased in patients with metastatic breast cancer. 4 Therefore, RANKL can be a strategic therapeutic target for patients with metastatic breast cancer. 5 Isoliquiritigenin (ISL) (Fig. 1A) is a flavonoid derived from licorice and shallot. 6 ISL has diverse pharmacological activities such as anti-inflammatory, anti-diabetic, anti-angiogenic, and anti-osteoclastic properties. [7] [8] [9] [10] In addition, ISL has strong anticancer effects in various types of cancers. [11] [12] [13] In breast cancer, ISL inhibits the metastasis of human breast cancer cells through In the present study to verify the potential of ISL as a promising agent for control of breast cancer bone metastasis, we investigated whether ISL could affect RANKL and OPG expression in osteoblastic cells stimulated with conditioned medium (CM) of metastatic breast cancer cells. Cell viability was measured using an MTT assay. The absorbance was determined at 570 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The blots were transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membrane was blocked with 5% skim milk in Tris-buffered saline with Tween 20 (TBST) and then incubated with the primary antibodies for COX-2 (1:1,000) and -actin (1:2,000) in 3% skim milk in TBST for 24 hours at 4 o C. After washing, the blots were incubated for 1 hour with secondary antibody coupled to horseradish peroxidase (1:2,000) and visualized with the ECL kit.
MATERIALS AND METHODS

Materials
Preparation of conditioned medium derived from
Statistical analysis
Statistical analysis was performed with SPSS statistical software ver. 21 (IBM, Endicott, NY, USA). Data are expressed as mean ± SE. Data were analyzed by means of the Student's t-test to express differences between the two groups. Results with values of P ＜ 0.05 and P ＜ 0.01 were considered statistically significant. (Fig. 1C) . In addition, we detected the expression level of membrane-bound RANKL in hFOB1.19 cells using fluorescence activated cell sorter analysis. CM of breast cancer cells increased the membrane-bound RANKL expression, but ISL reduced the CM-induced level of membrane-bound RANKL by 37% at 10 M (Fig. 1D ).
RESULTS
Isoliquiritigenin inhibited
Isoliquiritigenin inhibited the expression level of COX-2 in conditioned medium-stimulated osteoblastic cells
COX-2 is one of the well-known molecules that regulate the expression of RANKL. (Fig. 2A) . Western blot analysis also indicated that ISL significantly inhibited the protein levels of COX-2 in hFOB1.19 cells exposed to CM of MDA-MB-231 cells (Fig. 2B) .
DISCUSSION
Bone metastasis is frequently observed in patients with advanced breast cancer, and the mortality rate is significantly higher in patients with bone metastasis than in patients without bone metastasis. 2 Metastatic breast cancer cells metastasize to bone and secrete various osteolytic factors. 1 These factors stimulate osteoblasts that are important regulators of bone metabolism and abnormally increase the expression of RANKL, which is a key promoting factor for osteoclast differentiation and activation. 19 Consequently, excessive bone resorption by osteoclasts is rapidly increased in patients with metastatic breast cancer. 4 Several growth factors released from the bone matrix by osteoclast-mediated bone resorption contribute to the proliferation and survival of cancer cells. These amplified interactions between breast cancer cells and bone cells, referred to as a 'vicious cycle', make the condition difficult to treat. 20, 21 Therefore, controlling osteoblastic RANKL expression in the bone microenvironment with breast cancer metastases can be a promising strategy for the prevention and treatment of cancer-associated bone loss. ISL has potent anti-inflammatory, anti-angiogenic, and anticancer effects. 8, [10] [11] [12] [13] In particular, ISL prevents the metastatic potential of breast cancer cells through inhibition of matrix metalloproteinase activities and the PI3K/Akt signaling pathway. 14, 15 In our previous study, we found that ISL inhibited RANKL-induced osteoclastogenesis. 16 The RANKL and OPG from osteoblasts are important molecules in the differentiation of osteoclasts. 22 Thus, we further found that ISL at non-cytotoxic concentrations inhibited the RANKL/OPG ratio by blocking the expression of soluble and membrane-bound RANKL and the decrease in OPG production in human osteoblastic cells stimulated with CM of metastatic breast cancer cells. COXs are the enzymes that mediate the conversion of arachidonic acid to prostaglandins (PGs). 23 Whereas COX-1 is expressed constitutively in most tissues and plays an important role in the maintenance of homeostasis, COX-2 is an inducible enzyme contributing to the elevated production of PGs in inflammation and cancer. 24 Recent studies have demonstrated that COX-2 expression regulates the production of PGE2, which is one of the osteolytic factors involved in RANKL expression in osteoblasts. 17 Mice lacking COX-2 showed reduced bone resorption in response to parathyroid hormone. 18 PGE2 produced by cancer cells or osteoblasts binds to the osteoblastic EP4 receptor, which is one of the PGE receptor subtypes, and induces RANKL expression to stimulate bone resorption. 25 Additionally, COX-2 has been known to be involved in breast cancer bone metastasis. 
